Product Description
Relatlimab is a novel antibody that blocks lymphocyte-activation gene 3 (LAG-3), an immune checkpoint found on the surface of T cells. LAG-3 is often upregulated in melanoma, as is programmed death-1 (PD-1), the immune checkpoint inhibited by nivolumab. These data represent the first Phase II/III clinical trial results of a third-generation checkpoint inhibitor and the first clinical trial designed to compare combination checkpoint inhibitor therapy versus nivolumab monotherapy in melanoma. (Sourced from: https://www.mdanderson.org/newsroom/relatlimab-plus-nivolumab-improves-progression-free-survival-in-metastatic-melanoma.h00-159536589.html)
Mechanisms of Action: LAG3 Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Croatia | Czech | Denmark | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Latvia | Lithuania | Norway | Poland | Portugal | Slovakia | Sweden | Switzerland | United States
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, India, Ireland, Israel, Italy, Japan, Korea, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Singapore, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 61
Highest Development Phases
Phase 3: Colorectal Cancer|Melanoma|Non-Small-Cell Lung Cancer|Small Cell Lung Cancer
Phase 2: Acute Myeloid Leukemia|Adenocarcinoma|Bladder Cancer|Carcinoma, Merkel Cell|Chordoma|Chronic Lymphoid Leukemia|Diffuse Large B-Cell Lymphoma|Esophageal Cancer|Experimental Melanoma|Gastrointestinal Cancer|Genital Diseases, Female|Head and Neck Cancer|Hepatocellular Carcinoma|Hodgkin Lymphoma|Kidney Cancer|Liver Cancer|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, Non-Hodgkin|Multiple Myeloma|Oncology Solid Tumor Unspecified|Pregnancy Outcomes|Renal Cell Carcinoma|Sarcoma|Soft Tissue Cancer|Squamous Cell Carcinoma|Urinary Bladder Diseases|Uveal Melanoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2051240173 | P3 |
Recruiting |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
2033-11-11 |
|
| RELATIVITY 098 | P3 |
Active, not recruiting |
Melanoma |
2032-06-11 |
|
| RELATIVITY1093 | P3 |
Recruiting |
Non-Small-Cell Lung Cancer |
2030-07-30 |
|
| CA224-098 | P3 |
Unknown Status |
Melanoma |
2029-11-01 |